Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy infants

Update Il y a 4 ans
Reference: GSK112899_1

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

•To evaluate the safety and reactogenicity of one or two doses of the TB vaccine candidate (M72/AS01E) when given to healthy infants concomitantly with the Expanded Programme on Immunisation (EPI) regimen containing DTPwHepB/Hib + pneumococcal conjugate vaccine (PCV) + oral polio vaccine (OPV). •To evaluate the safety and reactogenicity of one or two doses of the TB vaccine candidate (M72/AS01E) when given to healthy infants after receiving the EPI vaccines containing DTPwHepB/Hib+PCV+OPV.


Inclusion criteria

  • Healthy volunteers (evaluation of safety and reactogenicity of TB vaccine when administered in healthy infants)

Links